Could TENS devices be a potential answer to the opioid crisis? If they are, it’ll be thanks to digital health.
Case in point is NeuroMetrix’s Quell device.
Transcutaneous electrical nerve stimulation (TENS) gizmos have been around for decades. But they’ve had a reputation for being unwieldy, with a bunch of wires and pads.
“TENS devices have been around for 40 years, and some of the reasons they’re not effective for chronic pain is that they are underpowered, not designed for 24/7 use, and they’re not dosing at the right levels for the individual. Treatment was left up to basically guess work,” said Frank McGillin, NeuroMetrix’s chief commercial officer. (Hear from McGillin in person at DeviceTalks Boston on Oct. 2.)
You may also like:
At DeviceTalks Boston, Tyler Shultz will give attendees an inside look at Theranos and how he was able to sound the alarm after he realized the company was falling apart. Shultz will take attendees behind the story that everyone is talking about: the rise and fall of Elizabeth Holmes and her diagnostic company, Theranos.
Join Shultz and 1,000+ medical device professionals at the 8th annual DeviceTalks Boston.